Kornimate/medical-research-clean huggingface dataset:
proteinuria in pre and post transplant

Conditions: Proteinuria

Summary: patients with focal segmental glomerulosclerosis (fsgs) who progress rapidly to end stage renal disease (esrd) are at highest risk for development of recurrence of proteinuria following kidney transplantation. this study will look at serum specimens pre and post transplant, as well as kidney transplant specimens pre and post reperfusion to identify where the defects has occured that results in recurrence of proteinuria in a given kidney transplant.

this study will retrospectively review patient's medical records for protein in the urine, blood creatinine and kidney biopsy results. also character of the fluid used to flush the kidney before transplant will be analyzed.

Eligibility criteria:
inclusion criteria: * kidney transplant recipients * pediatric males and females up to the age of 25 years old. exclusion criteria: * transplant recipients other than kidney

Keywords: focal segmental glomerulosclerosis
ultra low dose ct and use of iomeron 400 in pcd-ct

Conditions: Radiation Exposure; Lung Embolism; Lung Cancer; Pneumonia

Summary: evaluation of ultra low dose protocols and iomeron 400 contrast in pcd-ct


Eligibility criteria:
inclusion criteria: * ct scan for pulmonary nodule detection/follow up * ct scan for pneumonia detection/follow up exclusion criteria: * under 18 * bmi over 30
sintilimab with p-gemox regimen for newly diagnosed advanced extranodal natural killer/t-cell lymphoma, nasal type

Conditions: NK/T Cell Lymphoma Nos

Summary: the purpose of this multi-center,single arm,phase ⅱ clinical trail is to determine the safety and efficacy of sintilimab with p-gemox (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diagnosed advanced extranodal natural killer/t-cell lymphoma, nasal type (enktl)


Eligibility criteria:
inclusion criteria: * biopsy proved extranodal natural killer/t-cell lymphoma, nasal type; * newly diagnosed stage iii/iv patients; * at least one evaluable lesion； * ecog ps 0-2; * 18-75 years; without other malignancy; * proper functioning of the major organs. exclusion criteria: * hemophagocytic syndrome or aggressive nk cell leukemia; * involvement of central nervous system; * previously received treatment of chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma；
vitamin d supplementation in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: vitamin d has an immunomodulatory role. the aim of the present study is to assess the effect of vitamin d supplementation on exacerbation rate of copd patient with a vitamin d deficiency.

rationale: although vitamin d is well known for its function in calcium homeostasis and bone mineralisation, several studies have shown immunomodulatory effects of vitamin d. vitamin d deficiency is a common problem in patients with copd.. objective: to assess the effect of vitamin d supplementation on exacerbation rate in patients with copd and a vitamin d deficiency. study design: randomized, multi-center, double-blind, placebo-controlled intervention study. study population: 240 patients aged 40 years and older with copd and a vitamin d deficiency (25-hydroxyvitamin d concentration(25ohd)\ 400 iu per day will be excluded. intervention: participants will be randomly allocated to receive vitamin d3 16800 iu or placebo orally once a week during 1 year. main study parameters/endpoints: the primary endpoint is exacerbation rate. follow-up of the study: recruitment of participants is more troublesome than expected due to several reasons, more use of vitamin d supplements, higher 250hydroxyvitamin d levels than anticipated, less suitability due to presence other exclusion criteria. 29/8/2017 total number recruited participants is 119 10/7/2018 closure of recruitment, total number recruited participants is 158

Eligibility criteria:
inclusion criteria: * written informed consent * aged above 40 years * gold stages ii-iv and diagnosis copd confirmed by a medical doctor. * minimum of 10 packyears of smoking * vitamin d deficiency (a serum 25-hydroxyvitamin d lower than 50 nmol/l) * ability to comply with all study requirements exclusion criteria: * pregnant or lactating women, or subjects who intend to become pregnant within the study period * self-reported history of hypercalciemia or nephrolithiasis * self-reported presence of sarcoidosis * severe vitamin d deficiency (serum 25-hydroxyvitamin d lower than 15 nmol/l) * life expectation of less than 6 months on the basis of concurrent disease * interfering malignant diseases. * diagnosed osteoporosis * diagnosed asthma * diagnosed chronic kidney disease stage 4 or higher (estimated glomerular filtration rate ≤ 29 ml/min/1,73 m2) * serious mental impairment i.e. preventing to understand the study protocol or comply with the study aim; potentially unreliable patients and those judged by the investigator to be unsuitable for the study * use of maintenance dose oral corticosteroids * use of multivitamin supplement or vitamin d supplement which contains more than 400 iu per day * current participation in a clinical rehabilitation programme

Keywords: vitamin d, copd, immunomodulation, pulmonary function
using the gate control theory of pain to decrease pain during trigger finger corticosteroid injections

Conditions: Trigger Finger; Pain

Summary: the goal of this clinical trial is to investigate a new noninvasive technique that patients may use to help reduce the pain that they experience during cortisone injections for trigger fingers. it will also help provide information that may help support the gate control theory of pain as a framework for understanding and managing acute pain.the main questions it aims to answer are: can a physical stimulus near the site of cortisone injection reduce the pain experienced by the patient during the injection? does the physical stimulation or the cognitive distraction contribute more to pain relief? researchers will compare a physical stimulus near the injection site to a placebo (a similar task that theoretically should not reduce the experience of pain) to see if physical stimuli work to improve pain during injections. participants will: estimate how much pain they expect to experience during a cortisone injection receive a cortisone injection for a trigger finger while performing one of three possible actions (control, placebo task, or the investigated physical stimulus near the injection site) express how much pain they actually experienced during the injection


Eligibility criteria:
inclusion criteria: * are at least 18 years of age. * have been diagnosed with one or more "trigger fingers" of the index, middle, ring, or small fingers. * have decided to try a cortisone injection for one or more trigger fingers today as advised by your physician. * are able to read and understand these study procedures. exclusion criteria: * are severely visually impaired. * have a history of spinal cord injury. * have taken opioid pain medications in the last 28 days. * are currently pregnant.

Keywords: gate control theory of pain injection
continuation of serplulimab plus chemotherapy after first progression in advanced gastric or gastro-oesophageal junction adenocarcinoma: an open-label, randomised phase ii trial

Conditions: Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

Summary: this study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer(patients with her2 negative and pd-l1 cps≥5).patiens will recevie serplulimab plus chemotherapy ((oxaliplatin+capecitabine) as first-line treatment. after pd，patients will randomly 2：1 assigned to treatment：one group will receive serpluimab with paclitaxel,apatinib；another group will receive paclitaxel with or without ramucirumab.all of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent

stage one ：serplulimab 3mg/kg,d1,q2w or 4.5mg/kg,d1,q3w+oxaliplatin130mg/m2 iv.gtt d1+capecitabine 1000mg/m2 p.o.b.i.d d1\~d14,q3w stage two:serplulimab 3mg/kg,d1,q2w or 4.5mg/kg,d1,q3w+apatinib 250mg/qd+paclitaxel 135\~175mg/m2 iv.gtt,d1,q3w paclitaxel 135\~175mg/m2 iv.gtt,d1,q3w±ramucirumab 8mg/kg,d1,q2w

Eligibility criteria:
inclusion criteria: 1. volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (icf); be willing to follow and be able to complete all study procedures; 2. age ≥ 18 years and ≤ 75 years when icf is signed; 3. unresectable locally advanced, or metastatic gastric cancer including gastroesophageal junction cancer, and histopathologically confirmed diagnosis of adenocarcinoma; 4. never received systemic anti-tumor drug therapy before； 5. her2 negative and pd-l1 cps≥5; 6. measurable lesion according to recist v1.1 by irrc; 7. ecog score 0-1; exclusion criteria: 1. has other active malignancies within 5 years before the first administration of the study drug; 2. plan to or have previously received organ or bone marrow transplantation; 3. uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage; 4. have received any research drugs within 14 days before the first use of the study drugs.
phase ii double-blind, placebo-controlled study of the reinforcing effects of alprazolam in patients with anxiety

Conditions: Anxiety Disorder; Panic Disorder

Summary: objectives: i. determine whether the benzodiazepine alprazolam reinforces self-medication behavior in anxious patients with varying histories of using other drugs. ii. establish outpatient methods for the study of self-medication and drug reinforcement in patients vulnerable to prescription drug abuse or dependence. iii. evaluate the influence of alcohol and other non-prescription drug use as determinants of vulnerability in these patients. iv. identify personality, attitudinal, or other variables that might predict different patterns of self-medication. v. assess the effects of cognitive-behavioral therapy on alprazolam self-medication.

protocol outline: this protocol involves different experiments examining self-medication with anxiolytic medications in selected patients, and cognitive-behavioral therapy for anxiety. capsules are color coded and taken under double-blind conditions. compliance is monitored with the medication event monitoring system, which automatically registers the date and time each bottle is opened. the physician directs therapy administration, using some combination of the following: blind choice test, antianxiety agent(s), placebo, and cognitive-behavioral therapy.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * primary diagnosis of generalized anxiety or panic disorder determined by structured clinical interview for dsm iv * hamilton anxiety scale (ham-a) score at least 14 and profile of mood states (poms) tension/anxiety scale score at least 20 * concurrent diagnoses allowed: mild to moderate agoraphobia simple or social phobias secondary unipolar affective disorders * no current substance abuse, dependence, or substance abuse treatment drug-free urine sample required * no history of other primary axis i diagnosis other than tobacco dependence --prior/concurrent therapy-- * no prior formalized non-drug therapy for anxiety disorder * no concurrent prescription psychoactive medication * no history of benzodiazepine dependence --patient characteristics-- * age: 18 to 50 * other: medically healthy negative pregnancy test required no occupational requirement to work in hazardous situations

Keywords: anxiety disorder disease-related problem/condition neurologic and psychiatric disorders panic disorder rare disease
comparison of outcome of antibiotic coated vicryl vs non-coated vicryl in abdominal fascial closure after laparotomy in children

Conditions: Surgical Site Infection

Summary: we are investigating outcome of antibiotic coated vicryl versus non coated vicryl in terms of rate of surgical site infection and lebgth of hospital stay in children after lalaprotomy for perforated viscera. total 100 patients will be taken and 50 in each group.

pneumoperitoneum is typically a surgical emergency, particularly in children and more than 90% of occurrences are caused by perforation of the gastrointestinal tract and other hollow viscera. wound infections after abdominal surgery are still frequent types of nosocomial infections. sutures can be a source of wound infection and dehisence due to bacterial adherence and colonization. sutures coated with antibacterial agents have been developed in an attempt to reduce bacterial adherence and colonization of suture materials. the objective of the study is to compare the outcome of antibiotic coated vicryl versus non-coated vicryl in abdominal fascial closure after laparotomy in children in regards of surgical site infections. it will be a randomized controlled trial in which 100 patients admitted in children hospital lahore will be included. simple random sampling will be carried out. informed written consent will be taken from patients' guardian. the patients will be divided into two groups (50 in each group). group-a patients will undergo laparotomy closure with antibiotic coated vicryl while group-b patient will experience non-coated vicryl in abdominal fascial closure. all patients will be examined on 3rd, 7th and 30th post-operative day for wound infection according to southampton wound scoring system. data will be collected through predesigned proforma, which will be entered and statistically analyzed using spss version 24.0. for quantitative variables mean and standard deviation will be calculated and for qualitative variables frequency and percentages will be calculated. data will be presented in tables and graphs. chi-square test will be used to estimate the association between qualitative variables. p-value \<0.05 will be considered significant. it is expected that results of this study may be helpful for healthcare providers to provide appropriate treatment to the patients and to prevent them from wound related complications.

Eligibility criteria:
inclusion criteria: * • children with pneumoperitoneum / perforated viscus * children aged 0 day to 15 years * both genders exclusion criteria: * • malnourished children * children aged above 15 years * clean surgeries * low hb level * parents unwilling to take part

Keywords: ssis, anti biotic coated vicryl, laparotomy, triclosan coated vicryl, vicryl plus, surgical site infection, uncoated vicryl,
trial of xyrem® (sodium oxybate) for the treatment of narcolepsy

Conditions: Narcolepsy

Summary: this is a long-term, open-label, extension of the omc-sxb-7 trial. participants from the omc-sxb-7 open-label trial may be entered without any requirement as to length of participation in that trial. approximately 70 patients are expected to participate at up to 6 investigative centers located in canada. the trial will continue for up to 24 months or until marketing approval, whichever occurs sooner.

this trial will be conducted as a long-term, open-label, extension of the omc-sxb-7 trial. participants from the omc-sxb-7 open-label trial may be entered without any requirement as to length of participation in that trial. approximately 70 patients are expected to participate at up to 6 investigative centers located in canada. the trial will continue for up to 24 months or until marketing approval, whichever occurs sooner.

Eligibility criteria:
inclusion criteria: * remained on satisfactory treatment with xyrem® therapy in the omc-sxb-7 trial * signed and dated an informed consent

Keywords: narcolepsy cataplexy
serratus plane block for rib fractures

Conditions: Chest Trauma; Chest Pain

Summary: patients with ipsilateral multiple rib fractures will be randomized to receive either a single-shot ultrasound-guided serratus plane block, or a continuous serratus plane block within 24h from the chest trauma. primary outcome is the difference in forced respiratory volume (fev1) at 72h.

patients admitted in emergency department with a chest trauma and ipsilateral multiple rib fractures, will be randomized as described above. all patients will receive the serratus block with a ropivacaine 0.37% solution 20 ml. then, they will randomized to receive either a peripheral catheter placed above the 5th rib on the middle axillary line, or nothing. in all patients postoperative analgesia also include paracetamol 1g iv each 6h and a patient controlled analgesia (pca) of morphine set out as follow: bolus 1 mg, loch out 15 min, max 4 boluses each hour. in all patients an arterial blood sample for gas analysis and a fev1 will be achieved before the block, after 1 hour and at 72h.

Eligibility criteria:
inclusion criteria: * 2 o more ipsilateral rib fractures * trauma within 24h from hospital admission * informed consent exclusion criteria: * chest drain * head trauma * bilateral rib fractures * intensive care admission
feasibility of teleyoga for treatment of lyme disease

Conditions: Lyme Disease

Summary: primary aims: modify an existing teleyoga intervention to use with lyme disease (ld) patients and address the technical challenges of at-home teleyoga

participants with symptoms of lyme disease (n=15) will participate individually in a weekly tele-yoga class using an ipad loaned by the study. participants will choose where to attend these remote treatment sessions. yoga treatment will last 12 weeks. participants' subjective pain will be rated at baseline and end-of-treatment using a standard pain scale. also assessed will be participant adherence to study protocol by tracking treatment attendance

Eligibility criteria:
inclusion criteria: * diagnosis of probable lyme disease * has not begun new pain medications or other treatments in the last month * english literacy * wireless internet connection at home exclusion criteria: * participation in another concurrent clinical trial * back surgery within the last 12 months * unstable, coexisting mental illness or psychiatric condition * active, current suicidal intent or plan * attended or practiced yoga ≥ 1 x in the past 12 months

Keywords: yoga telehealth chronic pain
melatonin and nighttime blood pressure in african americans--24 mg study

Conditions: Hypertension

Summary: the purpose of this study is to test the effect of oral melatonin supplementation (24 mg per night for 4 weeks) on nighttime blood pressure in african americans with a history of elevated nighttime blood pressure.

the main outcome of interest is the mean nighttime blood pressure. the investigator is also trying to see the mechanism of action of melatonin on blood pressure by analyzing data from sleep studies to see if melatonin lowers blood pressure by providing a better quality of sleep or is that independent of the quality of sleep. the investigator is also looking into the effect of melatonin on sympathetic nervous system by measuring urinary catecholamines. finally, the investigator is looking into changes in vascular biology markers p-selectin and e-selectin) on melatonin.

Eligibility criteria:
inclusion criteria: * males or females ages 18 to 64 * prior history of elevated nighttime blood pressure (bp) ((systolic blood pressure (sbp) \> 115mmhg)) * taking no more than 2 antihypertensive medications * african american (self-defined by the participant) exclusion criteria: * secondary forms of hypertension * presence of other diseases requiring treatment with bp lowering medication * known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or history of cerebrovascular disease, including stroke and transient ischemic attacks) * diabetes mellitus (type 1 or 2) * cancer/malignancy other than nonmelanoma skin cancer * primary renal disease * serum creatinine \> 1.5 mg/dl in men or \> 1.4 mg/dl in women * severe anemia * liver enzymes \> 2.5 times upper limits of normal * hepatitis b, hepatitis c, or hiv positive as assessed by questionnaire * current treatment with or regular use of calcium channel blocking agents, cyclooxygenase-2 inhibitors (cox2-i), oral contraceptives, estrogen, sildenafil, vardenafil, tadalafil, antidepressants, corticosteroids, or warfarin * current use of melatonin or any sleep aids containing melatonin * regular consumption (1 or more times per week) of: vitamin methyl b12, st. johns wort, feverfew, black and white mustard seeds, wolf berry seed * severe sleep apnea * night work * women who are pregnant, breast feeding, attempting conception, or planning to attempt conception over the next 6 months.

Keywords: melatonin hypertension blood pressure cardiovascular sleep nighttime nocturnal catecholamines sympathetic nervous system endothelial function african american
study to evaluate the effect of xolair(omalizumab) on improving the tolerability of specific immunotherapy in patients with at least moderate persistent allergic asthma inadequately controlled with inhaled corticosteroids

Conditions: Asthma

Summary: in patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per us product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).

omalizumab is an fda approved anti-ige drug used to treat allergic asthma. this study is designed to give omalizumab 13 weeks prior to administering rapid build up of specific allergy shot, with an overlap of omalizumab and cluster therapy for 3 weeks. the cluster therapy will take 4 week to complete with maintenance dosage lasting an additional 6 weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis and history of moderate persistent allergic asthma * body weight \>/= 20kg and \</= 150kg * total serum ige \>/= 30 and \</= 700iu/ml * on a stable asthma treatment including corticosteroids for the preceding 4 weeks * non smoker for at least 1 year prior to visit 1 exclusion criteria: * patients with severe asthma * history of immunotherapy to any allergen within the past 3 years * history of anaphylactic allergic reaction * upper respiratory tract infection

Keywords: allergic asthma immunotherapy
unravelling intestinal fibrosis in ulcerative colitis

Conditions: Ulcerative Colitis (UC); Inflammatory Bowel Disease (IBD); Fibroblast Activation Protein Inhibitor

Summary: the main objectives are: (i) to identify candidate fibrotic cellular pathways in uc patients treated with a jak inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in uc patients using fapi-pet/ct imaging


Eligibility criteria:
inclusion criteria: * adults with confirmed diagnosis of uc - group 1 criterion: ≥18 years of age regardless of gender * group 2 criterion: ≥30 years of age for males and ≥40 years of age for females * active disease confirmed by endoscopy (endoscopic mayo score ≥ 2) * indication to start treatment with filgotinib and one of the following criteria: * active disease confirmed by intestinal ultrasound (bwt \&gt; 3 mm in at least one bowel segment and at least one other pathological ius parameter) or * increased crp (\&gt;5 mg/l) and/or fecal calprotectin levels (\&gt;250 mg/kg) exclusion criteria: * pregnancy * unable to provide informed consent * colorectal carcinoma or high-grade dysplasia

Keywords: pet ct fapi ibd ulcerative colitis filgotinib